651718-76-2

Upstream product

• 651718-75-1 (2S,3S)-[(2-benzyloxymethyl-5-oxotetrahydrofuran-3-yl)difluoromethyl]phosphonothioic acid O,O-diethyl ester 

Downstream Products

• 651718-91-1 5-O-benzyl-2,3-dideoxy-3-[(diethoxyphosphorothioyl)(difluoro)methyl]-4-O-(1H-imidazol-1-yl-carbonothioyl)-1-O-(triisopropylsilyl)-D-erythro-pentitol 
• 651718-80-8 diethyl (2R)-4-(benzyloxy)-1,1-difluoro-2-{2-[(triisopropylsilyl)oxy]ethyl}butylphosphonate 
• 651718-79-5 O,O-diethyl (2R)-4-(benzyloxy)-1,1-difluoro-2-{2-[(triisopropylsilyl)oxy]ethyl}butylphosphonothioate 
• 651718-82-0 diethyl (2R)-4-(benzyloxy)-2-{2-[(diethoxyphosphoryl)oxy]ethyl}-1,1-difluorobutylphosphonate 
• 651718-81-9 diethyl (2S)-4-(benzyloxy)-1,1-difluoro-2-(2-hydroxyethyl)butylphosphonate 
• 651718-77-3 5-O-benzyl-2,3-dideoxy-3-[(diethoxyphosphorothioyl)(difluoro)methyl]-1-O-(triisopropylsilyl)-D-erythro-pentitol 

Relevant academic research and scientific papers

Synthesis of acyclic nucleotide analogues possessing a difluoromethylene phosphonyl group at the side chain

A synthetic approach to a new type of acyclic nucleotide analogues 8 and 9 was examined. The design was based on acyclic modification of MRS 2179, a P2Y1-antagonist, and replacement of one of two phosphate groups characterized by MRS 2179 with an isosteric difluoromethylenephosphonyl group. The nucleotide analogues 8 and 9 were enantio-divergently prepared as their ester-protecting derivatives from a highly differentiated 1,5-pentanediol derivative possessing a difluoromethylenephosphonyl group at the 3-position.